HMG, or human menopausal gonadotropin, is a pharmaceutical preparation with both follicle-stimulating and luteinizing hormone activity. Originally obtained from the urine of postmenopausal women, it is associated with assisted reproductive medicine. The entry reviews ovarian follicle development and sperm-production research, distinguishing this hormone preparation from a single synthetic research peptide.
What Is HMG?
HMG (Human Menopausal Gonadotropin) is a combination gonadotropin pharmaceutical containing both FSH and LH activity. Originally extracted from the urine of postmenopausal women — where gonadotropin concentrations are naturally elevated following ovarian decline — modern formulations also include highly purified and recombinant preparations. Unlike synthetic research peptides, HMG is a well-established pharmaceutical class with decades of clinical use in assisted reproductive technology (ART).
In male fertility research, HMG is used to restore spermatogenesis in men with hypogonadotropic hypogonadism or TRT/AAS-induced infertility. Because it provides both FSH and LH activity simultaneously, HMG addresses both Leydig cell testosterone production and Sertoli cell-mediated spermatogenesis — a capability that hCG alone (LH-mimetic only) cannot fully replicate. In female fertility, HMG is used to stimulate multi-follicular development in IVF and ovulation induction cycles.
Mechanism of Action
The FSH component of HMG binds to FSH receptors on Sertoli cells in men (or ovarian granulosa cells in women), initiating intracellular signaling cascades that support spermatogenesis in men or follicle maturation in women. The LH component binds to LH receptors on Leydig cells in men (or ovarian theca cells in women), stimulating testosterone synthesis in men or supporting corpus luteum development and ovulation in women.
In men undergoing TRT or recovering from AAS use, exogenous androgens suppress endogenous LH and FSH via negative feedback on the pituitary, impairing spermatogenesis. HMG bypasses the suppressed pituitary entirely, delivering FSH and LH activity directly to the target tissues — a key mechanistic distinction from Gonadorelin, which acts upstream at the pituitary level and is therefore less reliable when pituitary gonadotroph function is suppressed by exogenous androgens.
HMG, hCG, and Gonadorelin: Key Distinctions
Understanding how HMG differs from its co-administered counterparts is essential for protocol design. These three compounds operate at different points in the reproductive axis:
hCG (LH-mimetic only): Directly stimulates Leydig cells via LH receptors, restoring intratesticular testosterone and testicular volume. Does not activate FSH receptors — often insufficient alone for complete spermatogenesis restoration.
HMG (FSH + LH): Provides dual gonadotropin activity. The FSH component directly activates Sertoli cells and spermatogenesis. Most effective when added to hCG protocols where sperm count or quality remains inadequate after hCG alone.
Gonadorelin (GnRH analog): Acts upstream at the pituitary, stimulating endogenous LH and FSH release. Requires an intact, responsive pituitary and pulsatile dosing. Substantially less reliable than direct gonadotropin therapy when pituitary function is suppressed by exogenous androgens.
Quick Reference
Member reference tables summarize the compound's research parameters.
Combined hCG + HMG protocols achieve pregnancy in ~40% of AAS-induced infertility cases over a median 26-month course. The FSH component is essential when hCG alone fails to restore adequate sperm parameters.
Hypogonadotropic Hypogonadism
First-line alongside hCG for male HH when pulsatile Gonadorelin delivery is unavailable or insufficient. Directly replaces the missing pituitary gonadotropin output.
Female Fertility / ART
Established
Ovulation Induction
Comparable ongoing pregnancy rates (~25–26% per cycle) to recombinant FSH in ART protocols. Highly purified hMG formulations are noninferior to Menopur for oocyte retrieval outcomes.
Multi-follicular Stimulation
Standard component of controlled ovarian stimulation protocols for IVF cycles requiring multiple follicle development.
TRT-Adjunct Fertility Restoration
Investigational
Fertility Augmentation
Added to hCG-based TRT protocols when sperm count or quality remains inadequate, providing the FSH signal that hCG cannot replicate. Typically initiated after 3 months of hCG monotherapy without adequate sperm response.
Research Protocols
As reported in cited literature and research-community logs (see Research Citations below), not a personal dosing recommendation.
This member section describes parameters reported in the research literature.
Included for harm-reduction awareness only, in the event this compound is encountered outside its labeled research use. Inclusion here does not imply RUO Codes endorses, recommends, or instructs human use.
This member section discusses research safety considerations and uncertainties.
Sourced exclusively from licensed pharmaceutical manufacturers (e.g., Ferring, IBSA, Organon); not available as a research-grade synthetic peptide from standard compound vendors.
Verified Marker
Lyophilized Presentation
Supplied as lyophilized powder requiring sterile reconstitution — the listed text specifies confirming vial integrity and matching diluent (sterile water or sodium chloride solution).
Verified Marker
IU Potency Verification
The described verification process includes verifying IU potency on the label: 75 IU and 150 IU per vial are standard pharmaceutical presentations.
Verified Marker
HP Formulation Equivalence
Highly purified (HP) formulations (Menopur, Gynogen HP) have documented clinical equivalence to recombinant FSH for oocyte retrieval outcomes in IVF.
Verified Marker
Cold-Chain Integrity
HMG degrades if stored above 8°C or exposed to light for extended periods. The listed research text specifies confirming cold-chain was maintained from manufacturer to delivery.
HMG, or Human Menopausal Gonadotropin, is a combination gonadotropin pharmaceutical with both FSH and LH activity. It was originally extracted from the urine of postmenopausal women, and modern formulations also include highly purified and recombinant preparations. The overview describes it as a well-established pharmaceutical class used in assisted reproductive technology research and clinical settings.
What has HMG been studied for?
HMG has been studied in male fertility research, including restoring spermatogenesis in men with hypogonadotropic hypogonadism or TRT/AAS-induced infertility. It has also been studied in female fertility, including multi-follicular development in IVF and ovulation induction cycles. Researchers have also examined it as an add-on to hCG-based protocols when sperm parameters stay inadequate.
How strong is the evidence for HMG?
The overview labels male spermatogenesis and female ART uses as established, while the TRT-adjunct use is labeled investigational. It reports pregnancy in about 40% of AAS-induced infertility cases with combined hCG and HMG, and about 25–26% ongoing pregnancy per cycle in ART, comparable to recombinant FSH. Detailed study quality is not provided.
How does HMG compare with hCG?
In the overview, hCG is an LH-mimetic that stimulates Leydig cells and does not activate FSH receptors, while HMG provides both FSH and LH activity. In studies of male fertility, HMG has been examined as an addition to hCG protocols when sperm count or quality remains inadequate, since its FSH component targets Sertoli cells.